Invest in

Drug-Patent Cliffs

8.0%
11.9%
0.6%

Expiring Patents, Aspiring Generics

Big Pharma is headed for a big change. And generics are getting ready to grab their share. Branded drugs with sales of $86 billion would lose patent protection during 2013 to 2017.[1] Some of the most lucrative targets for generics in 2013 include Eli Lilly’s Cymbalta, Biogen Idec’s Avonex and Merck KGaA's Rebif. These drugs generated global sales worth $10 billion in 2012.[2] Generic drugs, once available, are typically 30% to 80% cheaper than the brand names, and can capture 80% of the market within the first year.[3] Which means the next few years hold an unprecedented growth opportunity for the generic drug industry. And that has investors feeling feverish. See more
8.0%
11.9%
0.6%
Invest in Thematic Portfolios
Create your own customizable basket of up to 30 stocks or ETFs for just $9.95.
Motif Index 1 YR Return
Drug-Patent Cliffs Benchmark
With this Motif, you can buy the following basket of stocks for just $9.95:
Weight Segment & Stocks Symbol 1 MO / 1 YR Return
100% Generic Drugs 1.9%
19.7% Mylan N.V. MYL 9.2%
19.6% Taro Pharmaceutical Industries Ltd. TARO 14.5%
18.3% Dr. Reddy's Laboratories Ltd RDY 1.9%
11.4% The Medicines Company MDCO 60.3%
9.6% Abbott Laboratories ABT 17.9%
5.9% Akorn Inc. AKRX 15.4%
5.7% Mallinckrodt plc MNK 22.0%
5.3% Impax Laboratories Inc. IPXL 59.1%
2.3% Lannett Co Inc LCI 13.6%
1.5% Cambrex Corporation CBM 43.9%
0.7% Endo International PLC ENDP 74.8%

Quotes delayed 15 mins. Currently Feb 19, 2017 1:43:24 PM. Fields are marked with -- when data is unavailable.